ACTRN12619001103156尚未招募2 期
A Phase 2a randomised controlled trial measuring the effects on apnoea hypopnoea index (AHI) with nocturnal IHL-42X versus placebo in adults with obstructive sleep apnoea (OSA)
Cannvalate0 个研究点目标入组 30 人开始时间: 2019年8月9日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 21 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Aged between 21 and 65 years
- •Evidence of an Apnoea Hypopnea Index greater than or equal to 15 or less than or equal to 50. This criteria will be subject to the potential participant either being recently referred to the Austin sleep laboratory for ‘likely OSA’ or having a pre-existing diagnosis of OSA from a physician. This will be verified by the results of the PSG post V1, before randomisation occurs.
- •Have experimented with cannabinoids previously (self-disclosure). This includes any cannabis product (marijuana, skunk, ‘weed’)
- •No known allergic reaction to cannabis products with previous use
- •Ability to speak and read English
- •Have no history of past substance abuse or current abuse of illicit drugs
- •Physically well with no severe psychiatric, cardiac, renal, endocrine, gastrointestinal, or bleeding disorders
- •Not currently pregnant or lactating
- •Not taken any form of medication within 5 days of admission (except for prophylactic antibiotics, contraceptive pill or other routine medications to treat benign conditions, such as antibiotics to treat acne).
- •Provide a personally signed and dated informed consent indicating that the subject has been informed of all pertinent aspects of the trial
- •Be willing and able to participate in all scheduled visits, treatment plan, tests and other trial procedures according to the protocol
- •Willing to abstain from driving a vehicle for the duration of the study (minimum 6 weeks)
- •Willing to self-administer two capsules by mouth, 60 minutes before bedtime, each night for the duration of the study
- •Willing to complete a drug-administration log daily throughout participation
- •Willing to undergo three phone interviews throughout the duration of the study
排除标准
- •Aged under 21 or over 65 years
- •AHI of under 15 or over 50, or no doctors referral or diagnosis of sleep disorder
- •Other pre-existing sleep disorder (restless legs syndrome, narcolepsy, parasomnias etc.)
- •Currently using a positive airway pressure device (e.g. CPAP, VPAP), or other treatment for OSA including mandibular advancement splint, or positional device
- •ESS < 7 (excludes non-sleepy participants)
- •Inability to speak or read English
- •Non-compliance with study treatment following placebo run-in (missing greater than 20% of the treatment doses)
- •History of drug or substance abuse or current illicit drug abuse
- •Not physically well, or a history of severe psychiatric, cardiac, endocrine, renal, gastrointestinal, or bleeding disorders
- •Currently pregnant or breastfeeding
- •Currently taking medication (except for prophylactic antibiotics, contraceptive pill or other routine medications to treat benign conditions, such as antibiotics to treat acne)
- •Severe depression (a cut off of 20 and higher on the BDI)
- •Severe anxiety (a cut off of 16 and higher on the BAI).
- •No previous experience with cannabinoids
- •Current participation in any other trials involving investigational or marketed products within 30 days prior to the screening visit
研究者
相似试验
已完成
不适用
An exploratory study of dignity therapy for older people in care homesISRCTN37589515King's College London (UK)64
已完成
2 期
An exploratory study of Dignity Therapy for people with advanced cancerAdvanced cancerMalignant neoplasm of other and ill-defined sitesCancerISRCTN29868352King's College London (UK)40
招募中
2 期
Dose escalation trial for squamous cell carcinoma of head and neck using FMISO PET CTCTRI/2024/04/065373Varian Medical Systems Inc
尚未招募
1 期
The effect of a cannabidiol (medicinal cannabis) toothpaste and mouthwash on gingivitisGingivitisACTRN12619000882123Cannvalate (Australia)40
进行中（未招募）
1 期
Randomised trial to determine the efficacy of immunotherapy with natural killer cells in high-risk acute myeloid leukemiaewly diagnosed high-risk AML other than acute promyelocytic leukemia, =20% blastsMedDRA version: 17.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2013-003421-28-DETechnische Universität Dreden56